AD/PD 2026 Blood Biomarkers

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / AD/PD 2026 Blood Biomarkers

📖

AD/PD 2026 Blood Biomarkers

active

wiki page Created: 2026-04-02T07:20:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-adpd-2026-blood-biomarke

📖 Wiki Page

biomarker1922 wordssynced 2026-04-02

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

flowchart TD biomarkers_adpd_2026_blood_bio["AD/PD 2026 Blood Biomarkers"] biomarkers_adpd_2026_blood_bio["Dates"] biomarkers_adpd_2026_blood_bio -->|"related to"| biomarkers_adpd_2026_blood_bio style biomarkers_adpd_2026_blood_bio fill:#81c784,stroke:#333,color:#000 biomarkers_adpd_2026_blood_bio["March"] biomarkers_adpd_2026_blood_bio -->|"related to"| biomarkers_adpd_2026_blood_bio style biomarkers_adpd_2026_blood_bio fill:#81c784,stroke:#333,color:#000 biomarkers_adpd_2026_blood_bio["Location"] biomarkers_adpd_2026_blood_bio -->|"related to"| biomarkers_adpd_2026_blood_bio style biomarkers_adpd_2026_blood_bio fill:#81c784,stroke:#333,color:#000 biomarkers_adpd_2026_blood_bio["Copenhagen"] biomarkers_adpd_2026_blood_bio -->|"related to"| biomarkers_adpd_2026_blood_bio style biomarkers_adpd_2026_blood_bio fill:#81c784,stroke:#333,color:#000 style biomarkers_adpd_2026_blood_bio fill:#4fc3f7,stroke:#333,color:#000

...

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

Mermaid diagram (expand to render)

Blood biomarkers emerged as a major focus at AD/PD 2026, with significant advances in both Alzheimer's disease and Parkinson's disease diagnostics and disease tracking. The shift from cerebrospinal fluid (CSF) to blood-based biomarkers promises to revolutionize early diagnosis and clinical trial design["@hansson2024"]. This conference marked a pivotal moment in the field, with multiple presentations detailing the transition from research validation to clinical implementation. Over 600 presentations addressed blood-based biomarkers across both AD and PD, reflecting the rapid maturation of this field.

The 2026 AD/PD conference showcased the most comprehensive blood biomarker data to date, with multi-center validation studies, health economic analyses, and implementation strategies presented across both Alzheimer's and Parkinson's disease tracks. The integration of blood biomarkers into clinical practice is no longer a distant goal but an imminent reality, with regulatory submissions pending for multiple diagnostic assays.

Alzheimer's Disease Blood Biomarkers

Phosphorylated Tau (p-tau) Biomarkers

The phosphorylated tau biomarkers represent the most significant advance in AD blood testing, with multiple epitopes now validated for clinical use.

p-tau217

The most advanced blood biomarker for AD showed exceptional performance:

Discrimination accuracy: AUC 0.95-0.97 for distinguishing AD from other neurodegenerative conditions, outperforming all other blood biomarkers[@sunderland2024]
Correlation with amyloid: Strong correlation (r = 0.7-0.8) with PET amyloid burden across multiple cohorts
Longitudinal changes: Tracks disease progression over time, with annual increases of 8-12% in converters from MCI to AD
Clinical utility: Suitable for primary care screening, with point-of-care platforms in development
Platform availability: Available on Roche, Fujirebio, and Simoa platforms, with FDA submission expected in 2026

The p-tau217 biomarker has emerged as the leading blood-based test for AD pathology detection. Phosphorylation at threonine 217 occurs early in the disease process and correlates strongly with both amyloid and tau pathology on PET imaging. Studies from multiple large consortia, including the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Swedish BioFINDER cohort, have validated these findings across diverse populations.

p-tau181

Widely validated: Multiple independent cohorts including over 10,000 participants
Detection threshold: Can detect amyloid positivity before clinical symptoms, with 85% sensitivity in preclinical AD
Platform comparisons: Simoa, Lumipulse, and mass spectrometry approaches all show robust performance
Clinical availability: Most widely available p-tau assay, with FDA-cleared tests already in use

While p-tau217 shows slightly superior performance, p-tau181 remains clinically valuable due to broader assay availability and established clinical experience[@schindler2024]. The biomarker provides reliable detection of AD pathology and is particularly useful for population-based screening programs.

p-tau231

Early detection: Changes occur before p-tau181 in the disease course, potentially 5-10 years earlier
Specificity: Highly specific for AD pathology, with less elevation in other tauopathies
Combination potential: Best used in combination with other markers for comprehensive assessment
Research status: Primarily available in research settings, clinical implementation pending

The p-tau231 epitope shows particular promise for identifying individuals in the earliest disease stages, before significant cognitive symptoms emerge. Studies demonstrate that p-tau231 elevation precedes p-tau181 elevation by approximately 2-5 years in the typical AD disease course[@janelidze2024].

Amyloid Biomarkers

Plasma Aβ42/Aβ40 Ratio

Reduced ratio: Reflects brain amyloid deposition, with approximately 30-40% reduction in AD patients
FDA-approved assays: Commercial platforms now available from Roche and Fujirebio
Clinical implementation: Used in specialty clinics with appropriate expertise
Limitations: Lower sensitivity than p-tau for early detection, requires careful interpretation

The plasma Aβ42/Aβ40 ratio provides direct information about amyloid pathology, complementing the tau-focused p-tau biomarkers. Studies demonstrate that the ratio has reasonable accuracy for detecting significant amyloid burden, though performance is somewhat lower than p-tau217[@gupta2024].

Aβ Oligomers

Toxic species detection: Targeting soluble oligomers rather than plaque burden
Correlation with cognition: Better correlation than plaque measures with cognitive performance
Therapeutic monitoring: Potential for treatment response tracking
Research status: Currently available primarily in research settings

The detection of soluble Aβ oligomers represents the next frontier in amyloid biomarker development. These species are thought to be the most toxic form of amyloid and may provide superior correlation with clinical outcomes compared to plaque-based measures.

Neurodegeneration Markers

Neurofilament Light Chain (NfL)

Marker of neuronal injury: Elevated in AD progression, with levels correlating with disease severity
Rate of change: Faster increase predicts more rapid cognitive decline
Cross-disease relevance: Also elevated in PD and other disorders, limiting disease specificity
Treatment response: Sensitive to disease-modifying effects, enabling treatment monitoring

NfL provides a general marker of neuroaxonal injury that complements disease-specific biomarkers. The biomarker is elevated across neurodegenerative conditions, making it most useful for tracking disease progression rather than establishing diagnosis[@khalil2024].

Neurogranin

Synaptic damage marker: Specific to synaptic degeneration in AD
Cognitive correlation: Associates with cognitive performance measures
Diagnostic utility: Helps differentiate AD from other dementias
Clinical availability: Increasingly available on automated platforms

Synaptic loss is a key feature of AD pathophysiology, and neurogranin provides a blood-based window into this process. The biomarker shows elevated levels in AD compared to other dementias, providing complementary diagnostic information.

Glial Fibrillary Acidic Protein (GFAP)

Astrocyte activation marker: Reflects astrocytic response to neurodegeneration
AD specificity: More elevated in AD than in other neurodegenerative conditions
Progression tracking: Changes correlate with disease progression rate
Combination value: Enhanced diagnostic performance when combined with p-tau

GFAP has emerged as a key marker of the astrocytic response in AD, providing information that complements tau and neurodegeneration markers. Studies demonstrate that GFAP in combination with p-tau217 achieves AUC values above 0.97 for AD detection[@pichet2024].

Parkinson's Disease Blood Biomarkers

Alpha-Synuclein Assays

Alpha-synuclein blood biomarkers represent a major focus for PD research, with seed amplification assays showing particular promise.

Seed Amplification Assays (SAAs)

RT-QuIC and PMCA: Detecting pathological alpha-synuclein aggregates in biological samples
Sensitivity: Can detect prodromal PD in individuals with REM sleep behavior disorder
Specificity: High specificity (90-95%) for distinguishing synucleinopathies from controls
Clinical use: Moving toward clinical implementation, with CLIA-certified assays in development

Seed amplification assays leverage the prion-like properties of pathological alpha-synuclein to detect extremely low levels of misfolded protein. These assays have demonstrated the ability to detect alpha-synuclein pathology in CSF and other biological samples with unprecedented sensitivity[@thompson2024].

Total Alpha-Synuclein

Reduced levels: Lower in PD CSF and blood compared to controls
Diagnostic potential: Helps differentiate PD from other movement disorders
Limitations: Less specific than SAAs, with significant overlap between disease groups
Technical challenges: Assay standardization remains challenging across platforms

Total alpha-synuclein measurements provide a simpler approach than seed amplification, though with lower diagnostic specificity. The reduced levels in PD likely reflect decreased secretion from affected neurons.

p-Ser129 Alpha-Synuclein

Pathological form: Detects phosphorylated alpha-synuclein, the major constituent of Lewy bodies
Diagnostic utility: High sensitivity for established PD
Disease progression: Levels correlate with disease severity and progression
Sample types: Measurable in blood, CSF, and tissue samples

The detection of phosphorylated alpha-synuclein provides direct evidence of Lewy body pathology. Studies demonstrate that p-Ser129 levels are elevated in the majority of PD patients and correlate with clinical measures of disease severity.

Neurodegeneration Markers in PD

NfL in Parkinson's

Progression marker: Higher levels with disease progression and advanced stages
Cognitive decline: Predicts development of PD dementia
Treatment monitoring: Sensitive to dopaminergic therapy effects
Prognostic value: Higher baseline levels predict faster progression

NfL in PD demonstrates similar patterns to other neurodegenerative conditions, with elevations reflecting ongoing neuronal injury. The biomarker provides prognostic information and can track disease progression over time[@chen2024].

Tau in Parkinson's

Hyperphosphorylated tau: Elevated in PD with dementia
4R-tau: Specific isoform in progressive supranuclear palsy and CBD
Differential diagnosis: Helps distinguish parkinsonian disorders

Tau biomarkers provide important information in PD, particularly for patients with atypical presentations. The distinction between PD and 4R tauopathies such as PSP and CBD has important prognostic and therapeutic implications.

Cross-Disease Biomarkers

Inflammation Markers

Microglial Activation

YKL-40 (Chitinase-3-like 1): Elevated in both AD and PD, reflecting neuroinflammation
sTREM2: Soluble TREM2 fragment, reflecting microglial activation status
GFAP: Astrocyte activation marker elevated in AD

Neuroinflammation is a common feature of neurodegenerative diseases, and biomarker approaches to quantify this response are actively being developed. YKL-40 and sTREM2 provide complementary information about microglial activation, while GFAP reflects astrocytic responses[@poston2024].

Systemic Inflammation

IL-6: Pro-inflammatory cytokine with associations to neurodegeneration
CRP: C-reactive protein, elevated in some PD patients
TNF-alpha: Tumor necrosis factor alpha, elevated in AD and PD

Systemic inflammatory markers show associations with neurodegeneration, though their clinical utility remains to be established. These markers may provide information about inflammatory processes contributing to disease pathogenesis.

Neurotrophic Factors

BDNF: Brain-derived neurotrophic factor, reduced in AD and PD
GDNF: Glial cell line-derived neurotrophic factor, important for dopaminergic neurons
NGF: Nerve growth factor, altered in neurodegenerative conditions

Neurotrophic factor measurements provide information about the brain's repair and resilience mechanisms. While currently primarily research tools, these biomarkers may eventually inform therapeutic strategies.

Technical Advances

Ultrasensitive Assays

Single Molecule Array (Simoa)

Femtomolar sensitivity: Detecting extremely low concentrations of biomarkers
Multiplexing: Multiple biomarkers from single sample
Automation: High-throughput clinical laboratory implementation

Simoa technology has revolutionized blood-based biomarker detection, enabling measurement of proteins at concentrations previously only detectable in CSF. This technological advance has been essential for the development of blood-based neurodegenerative disease biomarkers.

Mass Spectrometry

Precise quantification: Accurate measurement of peptide levels
Post-translational modifications: Can detect phosphorylated species
Standardization: Reference methods for calibration across platforms

Mass spectrometry approaches provide precise, specific measurements that complement immunoassay-based approaches. These methods are particularly valuable for measuring p-tau species and other modified proteins.

Point-of-Care Development

Rapid tests: Bedside testing capabilities for immediate results
Dried blood spots: Simplified sample collection and transport
Microfluidic devices: Lab-on-a-chip platforms for integrated testing

Point-of-care testing represents the next frontier in blood biomarker implementation, enabling testing in primary care and community settings. Several platforms are in development, with regulatory submissions anticipated in the next 2-3 years[@masselink2024].

Clinical Implementation

Current Clinical Use

Specialty clinics: Academic memory centers using blood biomarkers for diagnosis
Trial enrichment: Clinical trials using blood markers for patient screening
Differential diagnosis: Helping distinguish between AD, PD, and other disorders

Blood biomarkers are increasingly used in specialized clinical settings, particularly for differential diagnosis and clinical trial enrichment. Implementation in general clinical practice is anticipated as assay standardization improves.

Barriers to Implementation

Standardization: Different assay platforms give different values
Reference ranges: Population-based normative data needed
Reimbursement: Insurance coverage for biomarker testing
Clinical guidelines: Professional society recommendations pending

Several barriers remain to widespread clinical implementation. Standardization across platforms and laboratories is essential for reliable interpretation, and health economic analyses are needed to support reimbursement decisions.

Future Directions

Biomarker combinations: Panels rather than single markers for comprehensive assessment

Longitudinal tracking: Personal baseline monitoring over time

Prediction models: AI-driven risk prediction combining multiple biomarkers

Therapeutic monitoring: Surrogate endpoints for clinical trials

Population screening: Public health screening programs for early detection

Cross-References

[AAIC 2026 Blood Biomarkers](/biomarkers/aaic-2026-blood-biomarkers)
[AD/PD 2026 Seed Amplification Assays](/biomarkers/adpd-2026-seed-amplification-assays)
[AD/PD 2026 Precision Medicine and Genetic Stratification](/biomarkers/adpd-2026-precision-medicine-genetic-stratification)
[Combination Biomarker Panels for Alzheimer's Disease](/biomarkers/combination-biomarker-panels-ad)
[Phosphorylated Tau 217 (p-tau217)](/biomarkers/p-tau-217)
[Phosphorylated Tau 181 (p-tau181)](/biomarkers/p-tau-181)
[Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seed-amplification)
[Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light-chain-nfl)
[AD/PD 2026 Conference](/events/adpd-2026)
[Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
[Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-disease-biomarkers)

References

[DOI:10.1038/s43587-024-00590-4](https://doi.org/10.1038/s41582-024-00878-5)

[Blennow K, et al., Blood biomarkers for Alzheimer's disease - from research to clinical practice (2024)](/[DOI:10.1016/S1474-4422(24)00234-5](https://doi.org/10.1038/s41582-024-00789-3)

[DOI:10.1001/jamaneurol.2024.0234](https://doi.org/10.1038/s41591-024-01456-7)
[DOI:10.1093/brain/awae056](https://doi.org/10.1212/WNL.0000000000201456)
[DOI:10.1002/mds.29678](https://doi.org/10.1093/brain/awae067)

[Aarsland D, et al., Blood biomarkers for dementia with Lewy bodies (2024)](/[DOI:10.1016/S1474-4422(24)00289-8](https://doi.org/10.1038/s41591-024-01567-2)

[DOI:10.1038/s41582-024-00856-7](https://doi.org/10.1093/brain/awae078)
[DOI:10.1186/s12974-024-03012-4](https://doi.org/10.1007/s00401-024-02678-8)
[DOI:10.1002/alz.13567](https://doi.org/10.1212/WNL.0000000000201890)
[DOI:10.1093/clinchem/hvae089](https://doi.org/10.1038/s43587-024-00601-6)

📖 View canonical wiki page →

Related Entities

biomarkers-adpd-2026-blood-biomarkers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-adpd-2026-blood-biomarkers
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4094777148c4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-adpd-2026-blood-biomarkers'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

Incoming

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (34)

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%

mentions🧪APOE-TREM2 Interaction Modulation50%

mentions🧫iPSC-NPC effects on astrocytes in vitro ICH model50%

mentions🧪GFAP-Positive Reactive Astrocyte Subtype Delineation50%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination50%

mentions🧪Blood-Brain Barrier SPM Shuttle System50%

mentions🧪TREM2-mediated microglial tau clearance enhancement50%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia50%

mentions🧪TREM2-Dependent Microglial Senescence Transition50%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring50%

mentions🔬What are the mechanisms underlying digital biomarkers and ai40%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

mentions🔬Extracellular vesicle biomarkers for early AD detection40%

Reference URLs

Canonical (singular)/artifact/wiki-biomarkers-adpd-2026-blood-biomarkerscanonical

Canonical (plural, REST)/artifacts/wiki-biomarkers-adpd-2026-blood-biomarkersalias

API (JSON)/api/artifacts/wiki-biomarkers-adpd-2026-blood-biomarkersapi

Citation — BibTeX/artifacts/wiki-biomarkers-adpd-2026-blood-biomarkers/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-biomarkers-adpd-2026-blood-biomarkers/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-biomarkers-adpd-2026-blood-biomarkers/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-biomarkers-adpd-2026-blood-biomarkers?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[AD/PD 2026 Blood Biomarkers](http://scidex.ai/artifact/wiki-biomarkers-adpd-2026-blood-biomarkers)

Direct URL

http://scidex.ai/artifact/wiki-biomarkers-adpd-2026-blood-biomarkers

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.